Our mission to be a global leader in generics starts with being a global leader in generic focused R&D. Teva is one of the few global pharmaceutical companies that has integrated scientific expertise across generic and specialty (branded) R&D capabilities. Fostering discovery and innovation, this unique combination of strengths and skills enables new ideas and advancements for the benefit of patients around the world.

In our development centers in the United States, Europe, Latin America, Israel, Japan and India, Teva’s researchers are constantly working to build a portfolio of products that serves patients. Our world-class scientists and doctors focus on being first to market, while ensuring the quality and affordability of our treatments and medicines. Teva’s R&D group has an exceptional track record in translating early drug opportunities into clinically-proven drug candidates by using cutting edge research in facilities that are fully equipped to support both good laboratory practice (GLP) and current good manufacturing practice (cGMP) regulations. Thanks to our research and development technology, our treatment deliveries have expanded beyond tablets, capsules, liquids, ointments and creams to a broad range of dosage forms and delivery systems. These include drug-device combination products, long acting release injectables, transdermal patches and films, and nasal suspensions.

As our portfolio grows, we are proud of our ability to take a medicine through the entire development process from an idea through to delivering it safely to patients around the world.